Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
So-Young International (SY) Earnings Preview: Strong Clinic Growth Ahead in Q3 2026

So-Young International (SY) Earnings Preview: Strong Clinic Growth Ahead in Q3 2026

Key Takeaways

  • So-Young International (SY) is expected to report its third-quarter 2026 results around November 23, 2026, before U.S. markets open, though the date has not yet been officially confirmed.
  • Consensus estimates point to a loss of roughly $0.05 per ADS on revenue of about $75.9 million, reflecting continued rapid top-line expansion alongside a still-narrowing bottom line.
  • Management has guided Q3 2026 aesthetic treatment services revenue to RMB 352–362 million, implying roughly 92% to 97% year-over-year growth in its core clinic business.
  • So-Young has beaten consensus earnings per share (EPS) estimates in five of its last six quarters, and it delivered record total revenue of RMB 505.2 million in Q2 2026, up 33% year over year.
  • Investors will focus on same-store sales, clinic openings, the number of profitable centers, and whether net losses continue to narrow as scale improves.
  • For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper context.
  • You can also explore Trending AI Robots to see AI-driven trading strategies currently capturing market interest.

Putting the Earnings in Context

So-Young International operates China's leading online-to-offline platform for medical aesthetics, connecting consumers with cosmetic treatment providers while expanding its own branded clinic network. The company's recent results have been defined by a powerful pivot: its legacy information and reservation services are shrinking, while its branded aesthetic centers are scaling rapidly. In Q2 2026, aesthetic treatment revenue surged roughly 130% year over year and accounted for the majority of total revenue. The Q3 report will show whether this clinic-led growth engine can keep accelerating even as the company continues to invest in new centers and manage group-level losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Analysts Are Expecting

Analysts expect So-Young to report a loss of about $0.05 per ADS on revenue near $75.9 million for the quarter ended September 30, 2026. That compares with a loss of $0.09 per ADS on revenue of roughly $54.3 million in the same period a year earlier, implying meaningful revenue growth alongside a narrower per-share loss. It is worth noting that Wall Street coverage of this small-cap name remains thin, so consensus figures should be treated with caution.

The company has already provided its own outlook. With its Q2 2026 results, management guided third-quarter aesthetic treatment services revenue to between RMB 352.0 million and RMB 362.0 million, representing 91.7% to 97.2% year-over-year growth. Beyond that top-line target, investors will watch same-store sales growth, the pace of new clinic openings, gross margin in the aesthetic treatment segment, and the number of centers turning profitable. So-Young has beaten consensus EPS estimates in five of its last six quarters, setting a high bar for execution. From what I see in the data, this track record suggests the company is delivering on its clinic expansion strategy.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 2026 report is cautiously constructive but centered on execution. So-Young has repeatedly topped consensus EPS estimates, and its shares responded positively following its record-setting Q2 release. Still, the stock remains volatile and well below prior highs, reflecting a thin analyst base and lingering questions about when the company will reach sustained group-level profitability. Key risk factors include rising costs tied to clinic expansion, elevated sales and marketing spending, and a continued decline in the legacy information and reservation services segment. Any sign that clinic growth is decelerating faster than guided, or that losses are widening rather than narrowing, could pressure the stock. I’m watching this closely as earnings approach.

What to Watch Going Forward

The most important metric to watch is aesthetic treatment services revenue, which has now guided for roughly 92% to 97% year-over-year growth in Q3 2026. This figure matters because it reflects both new clinic openings and same-store momentum, the two levers that underpin So-Young's long-term 1,000-center ambition.

Investors should also track profitability at the center level. In Q2 2026, 47 of 65 clinics were profitable, and 51 generated positive operating cash flow. As the network scales, the ratio of profitable centers will signal whether the company's standardized operating model is genuinely improving economics or simply growing for growth's sake.

Finally, watch the pace of loss reduction. Q2 2026 net loss narrowed 37% year over year to RMB 22.7 million, but the company is still not profitable at the group level. Any update on margin trends, customer acquisition efficiency, or the scaling back of loss-making businesses will help investors judge how quickly the company can close that gap. Upcoming catalysts include further guidance on clinic openings and supply-chain partnerships. One thing that stands out is how quickly the clinic network can turn more locations profitable.

Exploring AI Tools for This Analysis

In preparing this review, I turned to Tickeron’s AI Screener to filter comparable names in the sector and cross-check technical signals. It helped surface a few peers showing similar expansion patterns, which added useful context without replacing the core fundamentals. The tool’s customizable filters made it straightforward to scan for volatility and performance metrics that align with So-Young’s profile. Overall, it served as a practical supplement to traditional research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SY in downward trend: 10-day moving average moved below 50-day moving average on October 16, 2026

The 10-day moving average for SY crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SY as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

SY moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for SY moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for SY entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SY's RSI Indicator exited the oversold zone, 37 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for SY just turned positive on November 06, 2026. Looking at past instances where SY's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.

Following a +6.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SY advanced for three days, in 221 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

SY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.523). P/E Ratio (-0.846) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.430) is also within normal values, averaging (1.536). SY has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.011). P/S Ratio (1.067) is also within normal values, averaging (6.105).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -10%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 9%. DH experienced the highest price growth at 5%, while DRIO experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 54
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: 0 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of online information and reservation services related to medical aesthetics

Industry ServicestotheHealthIndustry

Industry
Internet Software Or Services
Address
No. 66 Xiangbin Road
Phone
+86 1087902012
Employees
2348
Web
https://www.soyoung.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.